ClinicalTrials.gg
RecruitingNCT06555068Updated Oct 22, 2026

A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of HRS-6209 in Combination with Fulvestrant and HRS-6209 in Combination with HRS-1358 in Advanced Unresectable or Metastatic Breast Cancer and Advanced Solid Tumors, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Oct 22, 2026Interventions changedTitle changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
528
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.

Planned enrollment
13th of 94
528 · median 71
Started
2024
the only one that year
Phase 1/2
4 of 95
none open now
Primary completion
2027-12
later than 15 of 22 live
Registered
92nd of 95
by date

Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 13th largest by planned enrollment of the 94 interventional ones that give a count, is the only one that started in 2024, is one of 4 in phase 1/2, reaches primary completion later than 15 of the 22 other live ones, and was the 92nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About fulvestrant

Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing fulvestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the safety, PK and efficacy of HRS-6209 in Combination with Fulvestrant, Letrozole, HRS-8080, HRS-1358 ,or HRS-9813 and HRS-8080,or letrozole and trastuzumab, with or without pertuzumab, or HRS-4508 and letrozole, with or without trastuzumab and/or pertuzumab, for advanced unresectable or metastatic breast cancer or HRS-9813 as monotherapy in Patients with Advanced Solid Tumors

03

Conditions studied

  • Advanced Unresectable or Metastatic Breast Cancer
  • Advanced Solid Tumors

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females aged 18-75 years (inclusive);
  2. performance status (PS) score of 0-1;
  3. Patients with histopathologically confirmed or unresectable locally advanced breast cancer;
  4. Patients with advanced malignant solid tumors confirmed by histopathology or cytopathology, who have failed standard treatment, or for whom no effective standard treatment regimen is available, or who are unable to receive further standard treatment.
  5. Menopausal status:

    1. Having had bilateral oophorectomy, or aged ≥ 60 years old; or
    2. Aged \< 60, natural menopause (defined as spontaneous cessation of regular menses for at least 12 consecutive months in the absence of other pathological or physiological causes) with E2 and FSH at levels; or
    3. Premenopausal or perimenopausal patients, agree to start or continue receive LHRH agonists during the study (exclude from the /QTc group).
  6. Disease progression evidenced by imaging during or after the last systemic anti-tumor treatment prior to the first dose (limited to the efficacy expansion stage);
  7. With at least one extracranial measurable target lesion at baseline per v1.1;
  8. of > 3 months;
  9. Adequate organ and marrow function as defined by the protocol;Female subjects of should agree to adopt effective measures during the study period and within 7months after the end of the study treatment; female subjects of childbearing potential must have a negative serum HCG test result within 7 days before enrollment in the study and must not be in the lactation;
  10. Voluntarily participate in this clinical study, be willing and able to comply with procedures related to clinical visits and study, and understand and have signed written .

Exclusion criteria

Exclusion Criteria:

  1. With symptomatic visceral deemed unfit for endocrine therapy by the investigator;
  2. With active , carcinomatous meningitis, spinal cord compression, or a history of primary tumors of the central nervous system;
  3. History of cardiovascular disease, including;
  4. Abnormal findings, which are judged by the investigator to be clinically significant and and need to intervene;
  5. Previous use of fulvestrant for cohort of HRS-6209 in combination with fulvestrant (efficacy expansion stage).
  6. With factors that affect oral medication, active gastrointestinal diseases, or other diseases that may obviously affect drug absorption, distribution, metabolism, or excretion;
  7. With clinically significant endometrial abnormalities, including but not limited to endometrial hyperplasia and dysfunctional uterine bleeding;
  8. Active infection or unexplained fever > 38.5 °C during the screening period or on the day of first dose;
  9. With uncontrollable chronic systemic complications as judged by the investigator.
  10. With active diseases, history of immunodeficiency and history of autoimmune diseases, history of diseases or syndromes that require systemic or drugs, other acquired ( infection) or congenital immunodeficiency, or history of organ transplantation (including bone marrow transplantation);
  11. With acute infection or active tuberculosis requiring medication.
  12. With a known history of clinically significant liver disease, untreated active hepatitis;
  13. Had other concurrent malignant tumors in the past 5 years, except: 1. Cervical carcinoma in situ that has been cured, 2. Second primary cancer that has been cured without recurrence within five years;
  14. Use of moderate and strong inhibitors within 1 week or moderate and strong CYP3A4 inducers within 2 weeks prior to the first dose;
  15. Use of any drugs with the risk of prolonging /QTc interval or causing torsade de pointes (TdP) within 4 weeks prior to the first dose, and with previous congenital QT interval prolongation syndrome or a family history of QT interval prolongation, implanted pacemakers or automatic implantable cardioverter defibrillators, uncorrectable electrolyte disorders, and other factors that may affect the QT/QTc study;
  16. Surgical treatment (except for needle or PICC catheterization or PORT catheterization), chemotherapy (except for 5-Fu drugs), immunotherapy, macromolecular targeted therapy, etc. within 4 weeks before the first dose; Received endocrine therapy, 5-FU chemotherapy or radiotherapy within 2 weeks before the first dose; Small molecule targeted drugs need to be washed out for 2 weeks or 5 half-lives (whichever is longer);
  17. Pregnant or lactating women, or females planning to become pregnant during the study period;
  18. With clear history of neural or mental disorders or with history of psychotropic abuse or drug abuse;

20) Subjects who are expected to receive other anti-tumor therapies or drugs during this study.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
528 participants (estimated)

Study arms

  • Experimental
    Treatment group A: HRS-6209 in Combination with Fulvestrant

    Drug: HRS-6209 in Combination with Fulvestrant

  • Experimental
    Treatment group E: HRS-6209 in Combination with HRS-1358

    Drug: HRS-6209 in Combination with HRS-1358

  • Experimental
    Treatment group B:HRS-6209 in Combination with Letrozole

    Drug: HRS-6209 in Combination with Letrozole

  • Experimental
    Treatment group C:HRS-6209 in Combination with HRS-8080

    Drug: HRS-6209 in Combination with HRS-8080

  • Experimental
    Treatment group D:HRS-6209 in Combination with HRS-8080

    Drug: HRS-6209 in Combination with HRS-8080

  • Experimental
    Treatment group F: HRS-6209 in Combination with HRS-1358

    Drug: HRS-6209 in Combination with HRS-1358

  • Experimental
    Treatment group G:HRS-6209 in Combination with HRS-9813 and Letrozole

    Drug: HRS-6209 in Combination with HRS-9813 and Letrozole

  • Experimental
    Treatment group H:HRS-6209 in Combination with HRS-9813 and HRS-8080

    Drug: HRS-6209 in Combination with HRS-9813 and HRS-8080

  • Experimental
    Treatment group I:HRS-6209 in Combination with HRS-9813 and HRS-8080

    Drug: HRS-6209 in Combination with HRS-9813 and HRS-8080

  • Experimental
    Treatment group PART3-A

    Drug: HRS-6209 in Combination with letrozole and trastuzumab

  • Experimental
    Treatment group PART3-B

    Drug: HRS-6209 in Combination with letrozole and trastuzumab and pertuzumab

  • Experimental
    Treatment group PART3-C-

    Drug: HRS-6209 in Combination HRS-4508 and letrozole

  • Experimental
    Treatment group PART3-D

    Drug: HRS-6209 in Combination HRS-4508 and letrozole and trastuzumab and pertuzumab

Interventions

  • DrugHRS-6209 in Combination with Fulvestrant

    Drug pages: HRS-6209 · Fulvestrant

    HRS-6209 in Combination with Fulvestrant

  • DrugHRS-6209 in Combination with HRS-1358

    HRS-6209 in Combination with HRS-1358

  • DrugHRS-6209 in Combination with Letrozole

    Drug pages: HRS-6209 · Letrozole

    HRS-6209 in Combination with Letrozole

  • DrugHRS-6209 in Combination with HRS-8080

    HRS-6209 in Combination with HRS-8080

  • DrugHRS-6209 in Combination with HRS-1358

    HRS-6209 in Combination with HRS-1358

  • DrugHRS-6209 in Combination with HRS-9813 and Letrozole

    Drug pages: HRS-6209 · HRS-9813 · Letrozole

    HRS-6209 in Combination with HRS-9813 and Letrozole

  • DrugHRS-6209 in Combination with HRS-9813 and HRS-8080

    HRS-6209 in Combination with HRS-9813 and HRS-8080

  • DrugHRS-6209 in Combination with letrozole and trastuzumab

    Drug pages: HRS-6209 · Letrozole · Trastuzumab

    HRS-6209 in Combination with letrozole and trastuzumab

  • DrugHRS-6209 in Combination with letrozole and trastuzumab and pertuzumab

    Drug pages: HRS-6209 · Letrozole · Trastuzumab · Pertuzumab

    HRS-6209 in Combination with letrozole and trastuzumab and pertuzumab

  • DrugHRS-6209 in Combination HRS-4508 and letrozole

    Drug pages: HRS-6209 · HRS-4508 · Letrozole

    HRS-6209 in Combination HRS-4508 and letrozole

  • DrugHRS-6209 in Combination HRS-4508 and letrozole and trastuzumab and pertuzumab

    Drug pages: HRS-6209 · HRS-4508 · Letrozole · Trastuzumab · Pertuzumab

    HRS-6209 in Combination HRS-4508 and letrozole and trastuzumab and pertuzumab

06

What researchers measure

Primary outcomes

  1. DLT (dose-limiting toxicity)-Stage I (dose exploration)

    Time frame: 28 days after the first dose

  2. MTD (maximum tolerated dose) -Stage I (dose exploration)

    Time frame: 28 days after the first dose

  3. RP2D (recommended phase II dose) -Stage I (dose exploration)

    Time frame: 28 days after the first dose

  4. (Serious) AEs-Stage I (dose exploration)

    Time frame: every week in Cycle 1 (28 days after the first dose), every 2 weeks in Cycle 2 (28 days after the second dose), every 4 weeks from Cycle 3 and thereafter (28 days after each dose), lasting about one year

  5. ORR ( objective response rate )-Stage II (efficacy expansion)

    Time frame: every 8 weeks lasting about one year

Secondary outcomes

  1. Cmax, ss (Stage I)

    Time frame: Cycle 1 (each cycle is 28 days) day 15、Cycle 2 (each cycle is 28 days) 、 Cycle 3 (each cycle is 28 days)、Cycle 4 (each cycle is 28 days)、、Cycle 5 (each cycle is 28 days)、Cycle 6 (each cycle is 28 days)

  2. Tmax, ss (Stage I)

    Time frame: Cycle 1 (each cycle is 28 days) day 15、Cycle 2 (each cycle is 28 days) 、 Cycle 3 (each cycle is 28 days)、Cycle 4 (each cycle is 28 days)、、Cycle 5 (each cycle is 28 days)、Cycle 6 (each cycle is 28 days)

  3. Cmin, ss(Stage I)

    Time frame: Cycle 1 (each cycle is 28 days) day 15、Cycle 2 (each cycle is 28 days) 、 Cycle 3 (each cycle is 28 days)、Cycle 4 (each cycle is 28 days)、、Cycle 5 (each cycle is 28 days)、Cycle 6 (each cycle is 28 days)

  4. AUCss (Stage I)

    Time frame: Cycle 1 (each cycle is 28 days) day 15、Cycle 2 (each cycle is 28 days) 、 Cycle 3 (each cycle is 28 days)、Cycle 4 (each cycle is 28 days)、、Cycle 5 (each cycle is 28 days)、Cycle 6 (each cycle is 28 days)

  5. ORR (objective response rate) (Stage I)

    Time frame: every 8 weeks lasting about one year

  6. BOR (best overall response) (Stage I)

    Time frame: every 8 weeks lasting about one year

  7. DoR (duration of response) (Stage I)

    Time frame: every 8 weeks lasting about one year

  8. CBR (clinical benefit rate) (Stage I)

    Time frame: every 8 weeks lasting about one year

  9. PFS (progression-free survival) (Stage I)

    Time frame: every 8 weeks lasting about one year

  10. (Serious) AEs (Stage II)

    Time frame: every week in Cycle 1 (28 days after the first dose), every 2 weeks in Cycle 2 (28 days after the second dose), every 4 weeks from Cycle 3 and thereafter (28 days after each dose), lasting about one year

  11. Cmax, ss (Stage II)

    Time frame: Cycle 1 (each cycle is 28 days) day 15、Cycle 2 (each cycle is 28 days) 、 Cycle 3 (each cycle is 28 days) 、Cycle 4 (each cycle is 28 days)、、Cycle 5 (each cycle is 28 days)、Cycle 6 (each cycle is 28 days)

  12. Tmax, ss (Stage II)

    Time frame: Cycle 1 (each cycle is 28 days) day 15、Cycle 2 (each cycle is 28 days) 、 Cycle 3 (each cycle is 28 days) 、Cycle 4 (each cycle is 28 days)、、Cycle 5 (each cycle is 28 days)、Cycle 6 (each cycle is 28 days)

  13. Cmin, ss(Stage II)

    Time frame: Cycle 1 (each cycle is 28 days) day 15、Cycle 2 (each cycle is 28 days) 、 Cycle 3 (each cycle is 28 days) 、Cycle 4 (each cycle is 28 days)、、Cycle 5 (each cycle is 28 days)、Cycle 6 (each cycle is 28 days)

  14. AUCss (Stage II)

    Time frame: Cycle 1 (each cycle is 28 days) day 15、Cycle 2 (each cycle is 28 days) 、 Cycle 3 (each cycle is 28 days) 、Cycle 4 (each cycle is 28 days)、、Cycle 5 (each cycle is 28 days)、Cycle 6 (each cycle is 28 days)

  15. BOR (best overall response) (Stage II)

    Time frame: every 8 weeks lasting about one year

  16. DoR (duration of response) (Stage II)

    Time frame: every 8 weeks lasting about one year

  17. CBR (clinical benefit rate) (Stage II)

    Time frame: every 8 weeks lasting about one year

  18. PFS (progression-free survival) (Stage II)

    Time frame: every 8 weeks lasting about one year

07

Study locations

1 of 1 sites recruiting
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
    • Jiong Wu · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2027, 40 months after the start.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 40 months is below that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2024
First posted
Aug 15, 2024
StartActual
Aug 12, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Aug 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Added Drug: HRS-6209 in Combination with letrozole and trastuzumab·Drug: HRS-6209 in Combination with letrozole and trastuzumab and pertuzumab·Drug: HRS-6209 in Combination HRS-4508 and letrozole·Drug: HRS-6209 in Combination HRS-4508 and letrozole and trastuzumab and pertuzumab. Arms added: Treatment group PART3-A·Treatment group PART3-B·Treatment group PART3-C-·Treatment group PART3-D
Oct 22, 2026
Title
A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients→A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Interventions Added Drug: HRS-6209 in Combination with letrozole and trastuzumab·Drug: HRS-6209 in Combination with letrozole and trastuzumab and pertuzumab·Drug: HRS-6209 in Combination HRS-4508 and letrozole·Drug: HRS-6209 in Combination HRS-4508 and letrozole and trastuzumab and pertuzumab. Arms added: Treatment group PART3-A·Treatment group PART3-B·Treatment group PART3-C-·Treatment group PART3-D
    Title A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients→A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors
    + 4 other changes: description, conditions, design details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06555068
Responsible party
Sponsor
First posted
Aug 15, 2024
Start date
Aug 12, 2024
Primary completion
Dec 2027 (estimated)
Completion
Aug 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Xiaonan Sheng
Contact
xiaonan.sheng.xs6@hengrui.com
+86 13524857678

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HRS-6209 · Fulvestrant · Letrozole · HRS-9813 · HRS-4508

Start the discussion